Filtered By:
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 769 results found since Jan 2013.
Children's Hospital Los Angeles is US site for $7M study of COVID-19 transmission
(Children's Hospital Los Angeles) Researchers at The Saban Research Institute of Children's Hospital Los Angeles, as well as in Nicaragua and New Zealand, are enrolling 250-325 households in a new study designed to study how COVID-19 spreads within households. The study was awarded $7.1 million by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Medicine and Health - September 14, 2020 Category: International Medicine & Public Health Source Type: news
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Considerations in Developing Medical Countermeasures Against Chemical Ocular Toxicity.
Abstract
The Chemical Countermeasures Research Program (CCRP) was established in 2006 by the National Institute of Allergy and Infectious Diseases (NIAID/NIH) on behalf of the National Institutes of Health Office of the Director (NIH OD). It is a trans-NIH initiative to expedite the discovery and early development of medical countermeasures (MCMs) that can reduce mortality and serious morbidity during and after large consequence public health emergency involving the deliberate or accidental large-scale release of highly toxic chemicals (HTCs).
PMID: 32916183 [PubMed - as supplied by publisher]
Source: Toxicology Letters - September 7, 2020 Category: Toxicology Authors: Yeung DT, Araj H, Harper JR, Platoff GE Tags: Toxicol Lett Source Type: research
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1)
The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and led by AstraZeneca.
Source: World Pharma News - September 1, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Single-use N95 respirators can be decontaminated and used again, study finds
N95 respirators,which are widely worn by health care workers treating patients with COVID-19and are designed to be used only once, can be decontaminated effectively and used up to three times, according to research by UCLA scientists and colleagues.An early-release version of their study has beenpublished online, with the full study to appear in September in the journal Emerging Infectious Diseases.N95 respirators reduce exposure to airborne infectious agents,including SARS-CoV-2, the virus that causes COVID-19,and are one of the key pieces of personal protective equipment used by clinical workers in preventing the spread ...
Source: UCLA Newsroom: Health Sciences - August 27, 2020 Category: Universities & Medical Training Source Type: news
FDA Issues Emergency Authorization For Convalescent Plasma To Treat Covid-19
(CNN) — The US Food and Drug Administration on Sunday issued an emergency use authorization for convalescent plasma to treat Covid-19, saying the “known and potential benefits of the product outweigh the known and potential risks of the product.”
The FDA said more than 70,000 patients had been treated with convalescent plasma, which is made using the blood of people who have recovered from coronavirus infections.
“Today I am pleased to make a truly historic announcement in our battle against the China virus that will save countless lives,” President Trump said at a White House briefing, referr...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 24, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Syndicated CBSN Boston CNN Coronavirus Source Type: news
NIH-supported scientists demonstrate how genetic variations cause eczema
(NIH/National Institute of Allergy and Infectious Diseases) New research supported by the National Institutes of Health delineates how two relatively common variations in a gene called KIF3A are responsible for an impaired skin barrier that allows increased water loss from the skin, promoting the development of atopic dermatitis, commonly known as eczema. This finding could lead to genetic tests that empower parents and physicians to take steps to potentially protect vulnerable infants from developing atopic dermatitis and additional allergic diseases.
Source: EurekAlert! - Medicine and Health - August 14, 2020 Category: International Medicine & Public Health Source Type: news
Test accurately IDs people whose gonorrhea can be cured with simple oral antibiotic
A test designed by UCLA researchers can pinpoint which people with gonorrhea will respond successfully to the inexpensive oral antibiotic ciprofloxacin, which had previously been sidelined over concerns the bacterium that causes the infection was becoming resistant to it.In research published in the peer-reviewed journal Clinical Infectious Diseases,a UCLA-led team found thatof106 subjectsthe test identified as having a strain ofgonorrhea called wild-type gyrA serine, all were cured with a single dose of oral ciprofloxacin. Though the test has been available for three years, this is the first time it has been systematicall...
Source: UCLA Newsroom: Health Sciences - August 12, 2020 Category: Universities & Medical Training Source Type: news
NIH trial to test antibodies and other therapeutics for mild, moderate COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are working with clinical sites to identify potential patient volunteers currently infected with SARS-CoV-2, the virus which causes COVID-19, who have mild to moderate disease not requiring hospitalization.
Source: EurekAlert! - Infectious and Emerging Diseases - August 4, 2020 Category: Infectious Diseases Source Type: news
Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
Source: World Pharma News - July 28, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Risk of Zika virus transmission from mother to unborn child much higher than expected
FINDINGSAccording to a new study by UCLA researchers and colleagues conducted in Brazil, 65% of children born to mothers infected withthe Zikavirusalsotested positive for the mosquito-borneinfection— a much higher rate than expected.The findings indicatethat even babies whohave no outward neurological or other symptoms associated with Zika can still be infected with the virus andare potentially at risk offuturedevelopmental problems. BACKGROUNDThe study representsthe first time that the mother-to-child transmission rate of Zika has been reportedfor a group of children who were tracked over several years — including f...
Source: UCLA Newsroom: Health Sciences - July 27, 2020 Category: Universities & Medical Training Source Type: news
Moderna ’s COVID-19 Vaccine Enters Final Testing Phase, As Researchers Dose the Study’s First Volunteer
Moderna Therapeutics and the National Institute of Allergy and Infectious Diseases (NIAID) announced today that researchers had injected the first volunteer in the first U.S. coronavirus vaccine to reach the final, phase 3 stage of testing.
That person received the shot at 6:45 am eastern time in Savannah, Geo., Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) told reporters during a briefing. Because the trial will randomly assign participants to receive either the vaccine or a placebo, and neither the researchers nor the volunteers will kn...
Source: TIME: Health - July 27, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Malvern antibiotics developer Venatorx lands NIH contract worth as much as $44M
A Chester County biopharmaceutical company focused on antibiotics could receive as much as $44.2 million under a research and development contract it received from a division of the National Institute of Health.
The contract was awarded to Venatorx Pharmaceuticals by the National Institute of Allergy and Infectious Diseases (NIAID).
Malvern-based Venatorx will use the funds to advance a novel series of penicillin-binding protein inhibitors it is developing to target multi-drug resistant acinetobacter…
Source: bizjournals.com Health Care:Biotechnology headlines - July 27, 2020 Category: Biotechnology Authors: John George Source Type: news
First Phase 3 clinical trial of a coronavirus vaccine in the United States begins
The investigational vaccine was developed by the biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial is to be conducted at nearly 100 US research sites, according to Moderna.
Source: CNN.com - Health - July 27, 2020 Category: Consumer Health News Source Type: news
